Disease Info Card

Dermatomyositis, Childhood Type

Information about Dermatomyositis, Childhood Type: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Dermatomyositis, Childhood Type

Most recent studies have shown that Dermatomyositis, Childhood Type shares some biological mechanisms with arthritis, arthritis-juvenile-rheumatoid, autoimmune-diseases, autoimmune-reaction, calcinosis, connective-tissue-diseases, dermatologic-disorders, dermatomyositis, exanthema, inflammation, lupus-erythematosus-systemic, muscle-weakness, myopathy, myopathy-idiopathic-inflammatory, myositis, pain, polymyositis, rheumatism, vasculitis, weakness.

Among the many pathways, these few ones have gauged particular interests from scientists studying Dermatomyositis, Childhood Type, and have been seen in publications frequently: Bone Mineralization, Bone Resorption, Cell Activation, Cell Adhesion, Cell Death, Chemokine Production, Coagulation, Complement Activation, Excretion, Immune Response, Localization, Macrophage Activation, Muscle Atrophy, Ossification, Pathogenesis, Programmed Cell Death, Regeneration, Secretion, T Cell Activation, Transport

Quite a number of genes have been found to play important roles in Dermatomyositis, Childhood Type, such as BEST1, BGLAP, CMAS, CRP, DMD, DMPK, HLA-DQA1, HLA-DRB1, HLA-DRB4, HLA-DRB5, HLA-E, IL6, INS, MUC1, PRB1, SPP1, THBS1, TNF, VWF. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.